Showing 7021-7030 of 9462 results for "".
- Modernizing Medicine and Miraca Life Sciences Partner to Create Enhanced EMR and Pathology Lab Integrationhttps://practicaldermatology.com/news/20130926-modernizing_medicine_and_miraca_life_sciences_partner_to_create_enhanced_emr_and_pathology_lab_integration/2459448/
- Phase I Trial for Implantable Melanoma Vaccine Beginshttps://practicaldermatology.com/news/20130910-phase_i_trial_for_implantable_melanoma_vaccine_begins/2459466/
- Do Physicians Mention Sunscreen Use Often Enough at Patient Visits?https://practicaldermatology.com/news/20130905-do_physicians_mention_sunscreen_use_often_enough_at_patient_visits/2459468/
- Acne-Specific Dermatology Platform Site Goes Livehttps://practicaldermatology.com/news/20130801-acne-specific_dermatology_platform_site_goes_live/2459485/
- Valeant Pharmaceuticals to Acquire Bausch + Lombhttps://practicaldermatology.com/news/20130528-valeant_pharmaceuticals_to_acquire_bausch__lomb/2459529/
- NeoStrata Teams with Avon on Anew Clinical Pro Line Eraserhttps://practicaldermatology.com/news/20120917-neostrata_teams_with_avon_on_anew_clinical_pro_line_eraser/2459739/In collaboration with NeoStrata Company,
- HHS Announces Next Steps To Promote Use Of Electronic Health Recordshttps://practicaldermatology.com/news/20120823-hhs_announces_next_steps_to_promote_use_of_electronic_health_records/2459749/Health and Human Services (HHS) Secretary Kathleen Sebelius
- New App Helps Physicians and Patients Take Control of Contact Dermatitishttps://practicaldermatology.com/news/20120820-new_app_helps_physicians_and_patients_take_control_of_contact_dermatitis/2459751/
- National Psoriasis Foundation Honors Experthttps://practicaldermatology.com/news/20120716-national_psoriasis_foundation_honors_expert/2459771/
- FDA Expands Dupixent CSU Indication to Children as Young as 2 Yearshttps://practicaldermatology.com/news/dupixent-approval-expanded-to-include-children-as-young-as-2-years-with-csu/2487479/The US Food and Drug Administration (FDA) has expanded the indication for Dupixent (dupilumab; Sanofi and Regeneron) to include pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. The label expansion, according